Replimune Group, Inc. (REPL)
14.69
-0.08
(-0.54%)
USD |
NASDAQ |
Aug 24, 16:00
14.69
0.00 (0.00%)
After-Hours: 20:00
Replimune Group Shareholders Equity (Quarterly) : 105.64M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 105.64M |
| March 31, 2026 | 166.16M |
| December 31, 2025 | 210.54M |
| September 30, 2025 | 263.34M |
| June 30, 2025 | 336.72M |
| March 31, 2025 | 415.84M |
| December 31, 2024 | 482.37M |
| September 30, 2024 | 381.46M |
| June 30, 2024 | 426.45M |
| March 31, 2024 | 374.51M |
| December 31, 2023 | 421.54M |
| September 30, 2023 | 465.17M |
| June 30, 2023 | 514.03M |
| March 31, 2023 | 555.29M |
| December 31, 2022 | 595.34M |
| September 30, 2022 | 384.07M |
| June 30, 2022 | 410.26M |
| March 31, 2022 | 411.23M |
| December 31, 2021 | 437.51M |
| Date | Value |
|---|---|
| September 30, 2021 | 457.41M |
| June 30, 2021 | 479.02M |
| March 31, 2021 | 498.73M |
| December 31, 2020 | 516.20M |
| September 30, 2020 | 261.39M |
| June 30, 2020 | 277.81M |
| March 31, 2020 | 183.72M |
| December 31, 2019 | 197.56M |
| September 30, 2019 | 120.64M |
| June 30, 2019 | 130.15M |
| March 31, 2019 | 137.86M |
| December 31, 2018 | 143.24M |
| September 30, 2018 | 150.04M |
| June 30, 2018 | 47.66M |
| March 31, 2018 | 58.29M |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | 20.09M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Moderna, Inc. | 6.761B |
| Kalaris Therapeutics, Inc. | 57.67M |
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 252.45M |
| Total Liabilities (Quarterly) | 146.80M |
| Debt to Equity Ratio | 1.060 |
| Current Ratio | 5.228 |
| Net Debt Paydown Yield | -0.77% |